Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANJAY SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1174609358
CMS profile
98913
Location
FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$92,909.44

235 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANJAY SHARMA

NPI 1174609358 · CMS profile ID 98913

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174609358?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANJAY SHARMA, NPI 1174609358, CMS profile ID 98913. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174609358?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SANJAY SHARMA, NPI 1174609358, CMS profile ID 98913. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174609358?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SANJAY SHARMA, NPI 1174609358, CMS profile ID 98913, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174609358?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

235 matching records · $92,909.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 235 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 235.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ipsen Biopharmaceuticals, Inc $14.0409/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893395925 CMS
Janssen Biotech, Inc. $21.6109/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543683 CMS
Janssen Biotech, Inc. $2.9909/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543687 CMS
E.R. Squibb & Sons, L.L.C. $92.5408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943535 CMS
E.R. Squibb & Sons, L.L.C. $442.9708/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943537 CMS
E.R. Squibb & Sons, L.L.C. $710.0008/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943547 CMS
Incyte Corporation $25.2308/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943013669 CMS
AstraZeneca Pharmaceuticals LP $21.8708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915189399 CMS
Gilead Sciences, Inc. $19.6308/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929559045 CMS
E.R. Squibb & Sons, L.L.C. $31.2308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943599 CMS
Lilly USA, LLC $16.6308/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918364393 CMS
BeiGene USA, Inc. $13.0908/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940792065 CMS
Celgene Corporation $25.3008/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943511 CMS
Novartis Pharmaceuticals Corporation $17.9008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894361057 CMS
GENZYME CORPORATION $15.2308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885397 CMS
Lilly USA, LLC $17.1208/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918343131 CMS
ABBVIE INC. $23.2908/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579853 CMS
Taiho Oncology, Inc. $18.0708/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924013255 CMS
E.R. Squibb & Sons, L.L.C. $0.4008/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943595 CMS
E.R. Squibb & Sons, L.L.C. $17.3208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943597 CMS
AstraZeneca Pharmaceuticals LP $24.2007/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915285609 CMS
AstraZeneca Pharmaceuticals LP $21.0907/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915871573 CMS
Celgene Corporation $23.8907/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943497 CMS
Merck Sharp & Dohme LLC $18.0307/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944353829 CMS
Blueprint Medicines Corporation $29.1407/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958943619 CMS
AstraZeneca Pharmaceuticals LP $13.9807/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914681599 CMS
E.R. Squibb & Sons, L.L.C. $16.9607/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943527 CMS
E.R. Squibb & Sons, L.L.C. $17.5507/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943507 CMS
Novartis Pharmaceuticals Corporation $19.0207/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894361053 CMS
Janssen Biotech, Inc. $27.6107/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543651 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.8907/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930593543 CMS
Janssen Biotech, Inc. $3.7907/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543691 CMS
Amgen Inc. $18.1507/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939213653 CMS
Astellas Pharma US Inc $12.7307/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940218999 CMS
Amgen Inc. $1,050.7506/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845857 CMS
Celgene Corporation $19.6806/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943501 CMS
Amgen Inc. $5.5006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845863 CMS
Amgen Inc. $2,800.0006/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845859 CMS
Amgen Inc. $467.0006/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845861 CMS
Janssen Biotech, Inc. $21.6606/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543671 CMS
Amgen Inc. $605.1506/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845865 CMS
Amgen Inc. $125.0006/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939845867 CMS
Novartis Pharmaceuticals Corporation $14.7306/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894361049 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943505 CMS
Gilead Sciences, Inc. $20.6706/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929559053 CMS
Merck Sharp & Dohme LLC $4,270.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944038513 CMS
Janssen Biotech, Inc. $5.0006/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885543655 CMS
Merck Sharp & Dohme LLC $75.0006/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944038503 CMS
GENZYME CORPORATION $1,026.2706/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885435 CMS
E.R. Squibb & Sons, L.L.C. $97.0906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932943503 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $130,210.51 365
PY2020 $28,389.21 134
PY2021 $36,581.07 153
PY2022 $92,909.44 235
PY2023 $124,134.79 282
PY2024 $182,104.29 291
PY2025 $73,881.35 245

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $129,916.67 5
PY2024 Principal investigator $82,234.80 76
PY2023 Recipient $32.78 1
PY2023 Principal investigator $67,281.13 24
PY2022 Principal investigator $147,623.09 123
PY2021 Principal investigator $268,178.21 445
PY2020 Recipient $13,263.00 1
PY2020 Principal investigator $169,841.94 10
PY2019 Recipient $11,736.68 2
PY2019 Principal investigator $19,990.62 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,022.40 03/26/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1185541998
Principal investigator 1 AstraZeneca Pharmaceuticals LP $113,544.27 03/12/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185542000
Principal investigator 1 Exelixis Inc. $2,025.00 01/17/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222383152
Principal investigator 1 Exelixis Inc. $3,375.00 01/17/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222383154
Principal investigator 1 Exelixis Inc. $1,950.00 01/17/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222383156